Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5793639 | 1.00 | HRH3 (0.56) | HRH3SIGMAR1KMT2AMEN1KDM4E | |
| SCHEMBL5793644 | 1.00 | HRH3 (0.56) | HRH3SIGMAR1KMT2AMEN1KDM4E | |
| SCHEMBL5796881 | 0.89 | FAAH (0.52) | HRH3KDM4EALDH1A1FAAHCYP2D6 | |
| SCHEMBL5796879 | 0.89 | FAAH (0.52) | HRH3KDM4EALDH1A1FAAHCYP2D6 | |
| SCHEMBL5796884 | 0.89 | FAAH (0.52) | HRH3KDM4EALDH1A1FAAHCYP2D6 | |
| SCHEMBL5796896 | 0.87 | HRH3 (0.55) | HRH3ACHE | |
| SCHEMBL5796894 | 0.87 | HRH3 (0.55) | HRH3ACHE | |
| SCHEMBL5796893 | 0.87 | HRH3 (0.55) | HRH3ACHE | |
| SCHEMBL5796707 | 0.87 | FAAH (0.55) | HRH3KDM4EALDH1A1FAAHLTA4H | |
| SCHEMBL5796712 | 0.87 | FAAH (0.55) | HRH3KDM4EALDH1A1FAAHLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006024955-A1 | AZABICYCLIC AMINE HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060047114-A1 | Azabicyclic amine histamine-3 receptor antagonists | PFIZER INC | 2006-03-02 | — | — | US | claimed |
| US-20060047114-A1 | Azabicyclic amine histamine-3 receptor antagonists | PFIZER INC | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047114-A1 | Azabicyclic amine histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | HRH3 1/4885SIGMAR1 1354/4885KMT2A 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.